Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | AOC2 | O75106 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16542117 | 0.91 | SMN1; SMN2 (0.83) | SMN1; SMN2GAARAB9APOLBEPHX2 | |
| SCHEMBL934891 | 0.89 | AOC2 (0.64) | SMN1; SMN2GAARAB9AMEN1KMT2A | |
| SCHEMBL24819419 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2GAARAB9APOLBEPHX2 | |
| SCHEMBL2456637 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2GAARAB9APOLBEPHX2 | |
| SCHEMBL24935012 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2GAARAB9APOLBEPHX2 | |
| SCHEMBL15804424 | 0.84 | KMT2A (0.59) | SMN1; SMN2GAARAB9AMEN1KMT2A | |
| SCHEMBL16612118 | 0.84 | AOC2 (0.54) | SMN1; SMN2GAAEPHX2MEN1KMT2A | |
| SCHEMBL12780814 | 0.84 | AOC3 (0.64) | SMN1; SMN2GAARAB9AMEN1KMT2A | |
| SCHEMBL17183464 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2GAARAB9APOLBEPHX2 | |
| SCHEMBL10746702 | 0.83 | MEN1 (0.71) | SMN1; SMN2GAARAB9APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, FABP4 | SMN1; SMN2 3635/4885GAA 1688/4885RAB9A 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.